MA28017A1 - Compositions ophtalmiques traitant l'hypertention oculaire - Google Patents

Compositions ophtalmiques traitant l'hypertention oculaire

Info

Publication number
MA28017A1
MA28017A1 MA28846A MA28846A MA28017A1 MA 28017 A1 MA28017 A1 MA 28017A1 MA 28846 A MA28846 A MA 28846A MA 28846 A MA28846 A MA 28846A MA 28017 A1 MA28017 A1 MA 28017A1
Authority
MA
Morocco
Prior art keywords
sub
hypertention
ophthalmic compositions
treating ocular
sup
Prior art date
Application number
MA28846A
Other languages
English (en)
Inventor
Meng Hsin Chen
James B Doherty
Luping Liu
Swaminathan Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA28017A1 publication Critical patent/MA28017A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés ayant la formule (I) constituant de puissants bloquants de canal potassique ou des compositions desdits composés pour le traitement du glaucome et d'autres états conduisant à une pression intraoculaire élevée dans l'¿il d'un patient. L'invention concerne également l'emploi desdits composés pour réaliser un effet neuroprotecteur pour l'¿il d'un mammifère, particulièrement de l'homme, ou un sel pharmacologiquement acceptable, un ester hydrolysable in vitro, un énantiomère, un diastéréomère ou un mélange de ceux-ci. La formule (II) représente aryle en C6 à C10 ou hétérocyclyle en C3 à C10, ledit aryle ou hétérocyclyle pouvant être facultativement substitué avec 1 à 3 groupes choisis parmi Ra ; Z représente (CH2)nPO(OR)(OR*).
MA28846A 2003-09-04 2006-03-01 Compositions ophtalmiques traitant l'hypertention oculaire MA28017A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50009503P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
MA28017A1 true MA28017A1 (fr) 2006-07-03

Family

ID=34312181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28846A MA28017A1 (fr) 2003-09-04 2006-03-01 Compositions ophtalmiques traitant l'hypertention oculaire

Country Status (20)

Country Link
US (1) US7410992B2 (fr)
EP (1) EP1663987B1 (fr)
JP (1) JP4546961B2 (fr)
KR (1) KR20060090801A (fr)
CN (2) CN102558231B (fr)
AT (1) ATE425971T1 (fr)
AU (1) AU2004272546B2 (fr)
BR (1) BRPI0414102A (fr)
CA (1) CA2537410C (fr)
DE (1) DE602004020079D1 (fr)
EC (1) ECSP066404A (fr)
IL (1) IL174068A0 (fr)
IS (1) IS8306A (fr)
MA (1) MA28017A1 (fr)
MX (1) MXPA06002515A (fr)
NO (1) NO20061505L (fr)
NZ (1) NZ545401A (fr)
RU (1) RU2006110625A (fr)
WO (1) WO2005026128A1 (fr)
ZA (1) ZA200601321B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507521A (ja) * 2004-07-20 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼科用組成物
BR112012024476A2 (pt) * 2010-03-26 2017-03-01 Galderma Res & Dev método para fornecer um tratamento seguro e efetivo da telangiectasia e método de produzir um produto embalado
WO2012046708A1 (fr) * 2010-10-08 2012-04-12 Ａｘｉｓ株式会社 Agent diagnostique, méthode diagnostique et agent thérapeutique pour traiter la fibromyalgie
WO2012139495A1 (fr) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de minéralocorticoïdes
CN110256314B (zh) * 2019-06-28 2020-12-15 南京林业大学 一种β-芳基酮类化合物的制备方法及其产品

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
WO1989010757A1 (fr) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Nouvelle preparation ophtalmique pour le traitement de glaucomes
JP2721414B2 (ja) * 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
EP0724443A4 (fr) 1993-06-08 1997-09-10 Vide Pharmaceuticals Procedes et comositions d'abaissement de la pression intra-oculaire
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
WO2001046140A1 (fr) 1999-12-22 2001-06-28 Pfizer Products Inc. Agonistes selectifs au recepteur ep4 dans le traitement de l'osteoporose
CA2396319A1 (fr) * 2000-01-18 2001-07-26 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
AU2001216072A1 (en) 2000-03-17 2001-10-03 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
SK5562003A3 (en) 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
WO2003105847A1 (fr) * 2002-06-14 2003-12-24 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
JP2006510742A (ja) * 2002-11-08 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼科組成物
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
EP1663221A4 (fr) * 2003-09-04 2009-04-22 Merck & Co Inc Compositions ophtalmiques pour traiter l'hypertension oculaire

Also Published As

Publication number Publication date
NO20061505L (no) 2006-04-27
ZA200601321B (en) 2007-05-30
CA2537410A1 (fr) 2005-03-24
DE602004020079D1 (de) 2009-04-30
RU2006110625A (ru) 2006-08-10
IL174068A0 (en) 2006-08-01
CN1845904A (zh) 2006-10-11
US7410992B2 (en) 2008-08-12
AU2004272546B2 (en) 2007-10-18
EP1663987B1 (fr) 2009-03-18
CN102558231B (zh) 2015-05-27
KR20060090801A (ko) 2006-08-16
EP1663987A1 (fr) 2006-06-07
NZ545401A (en) 2008-10-31
US20070010491A1 (en) 2007-01-11
WO2005026128A1 (fr) 2005-03-24
MXPA06002515A (es) 2006-06-20
ECSP066404A (es) 2006-09-18
IS8306A (is) 2006-02-16
JP4546961B2 (ja) 2010-09-22
JP2007504233A (ja) 2007-03-01
ATE425971T1 (de) 2009-04-15
CN102558231A (zh) 2012-07-11
BRPI0414102A (pt) 2006-10-31
CA2537410C (fr) 2009-08-11
AU2004272546A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2005002520A3 (fr) Compositions ophtalmiques destinees au traitement d'hypertension oculaire
WO2006044425A3 (fr) Compositions ophtalmiques de traitement de l'hypertension oculaire
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
WO2004103279A3 (fr) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles servant d'agonistes du recepteur s1p
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
MX2007006504A (es) Derivados de malonamida como inhibidores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer.
WO2005020917A3 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
WO2007025897A3 (fr) Derives de benzooxazole, oxazolopyridine, benzothiazole et thiazolopyridine
MA28017A1 (fr) Compositions ophtalmiques traitant l'hypertention oculaire
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
WO2004043354A3 (fr) Compositions ophtalmiques pour traiter l'hypertension oculaire
TW200740760A (en) Malonamide derivatives
DE60003435D1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
WO2006020003A3 (fr) Compositions ophtalmiques traitant l'hypertension oculaire
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
CA2831025C (fr) Composition pharmaceutique pour la prevention ou le traitement de la degenerescence maculaire
CA2534634A1 (fr) Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv
DE69518706D1 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
WO2008030390A3 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom
TW200509889A (en) Aniline derivatives